Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Tocilizumab Stories

2013-12-07 23:02:25

MarketReportsOnline.com offers “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” in its store. Key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report. Dallas, TX (PRWEB) December 07, 2013 The report titled "Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)" provides an in-depth...

2013-11-12 00:21:56

LUGANO, Switzerland, November 12, 2013 /PRNewswire/ -- Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their...

2013-10-24 12:26:15

EU5 Payers Agree that the Requirement for Direct Comparative Data Is Increasing in the Highly Competitive RA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results from the ADACTA trial, which showed that Roche's RoActemra is superior to AbbVie's Humira as a monotherapy in biologics-naive...

2013-10-10 08:26:50

Oral Agents Could Alter the Treatment Algorithm, After Establishing Clinical Profiles at Least Comparable to TNF-alpha Inhibitors, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market will experience moderate growth over the next decade as sales increase from $12.3 billion in...

2013-09-30 23:30:09

Reportbuyer.com just published a new market research report: Rheumatoid Arthritis (RA): World Drug Market 2013-2023. London (PRWEB) September 30, 2013 Report Details Now discover trends, opportunities and revenue prospects for treating rheumatoid arthritis Where's the arthritic treatment market heading? Visiongain's updated report gives you forecasted revenues to 2023 for drugs treating human rheumatoid arthritis (RA). There you find R&D trends, outlooks and commercial...

2013-09-24 11:22:59

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative. New treatment recommendations that guide physicians caring for children with systemic JIA are now published in the ACR journals, Arthritis & Rheumatism and Arthritis Care &...

2013-06-19 08:30:19

One of the Top Unmet Needs in RA is for Therapies with Greater Ability to Induce Remission Compared with Current Treatments, According to a New Report from Decision Resources BURLINGTON, Mass., June 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis, the majority of surveyed U.S. and European rheumatologists cite a therapy's induction of...

2013-05-15 00:21:05

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled...

2009-01-14 07:00:00

Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that growth opportunities for Roche/Chugai's Actemra (marketed as RoActemra in Europe) will propel Roche to sixth position in the rheumatoid arthritis market by 2012. Driving factors include...

2008-12-04 00:30:00

NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). As a result of the FDA's evolving Risk Evaluation and Mitigation Strategy (REMS)...